<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39372362</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2641-6549</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PHAGE (New Rochelle, N.Y.)</Title><ISOAbbreviation>Phage (New Rochelle)</ISOAbbreviation></Journal><ArticleTitle>Aerosolic Application of Phages Against <i>S. infantis</i> on Plates and Chicken Skin.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>129</EndPage><MedlinePgn>126-129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/phage.2023.0037</ELocationID><Abstract><AbstractText>Phages are known as a promising method to combat antimicrobial resistance (AMR) in the human and veterinary sector. Use of phage aerosols enormously increases the application field, although the impact on the infectivity of phages during nebulization needs to be evaluated. In this study <i>S. infantis</i> was treated on plates and chicken skin with nebulized phage particles of the <i>Myoviridae</i> type, identified by transmission electron microscopy, using a commercial nebulizer primarily used for H<sub>2</sub>O<sub>2</sub> disinfection. The reduction of bacterial number by aerosol applied phage particles was evaluated. It could clearly be shown that the phage particles were able to infect <i>Salmonella</i> after being nebulized using ultrasound technology. Further studies on other types of phages as well as other conditions must be performed to standardize the aerosolic application of phages.</AbstractText><CopyrightInformation>Copyright 2024, Mary Ann Liebert, Inc., publishers.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winkelmayer</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathammer</LastName><ForeName>Krista</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Requat</LastName><ForeName>Theres</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matt</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ljuhar</LastName><ForeName>Davul</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Braincon GmbH &amp; Co KG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jäger</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Braincon GmbH &amp; Co KG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kernmauner</LastName><ForeName>Friedrich</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Braincon GmbH &amp; Co KG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naemi</LastName><ForeName>Seyed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Braincon GmbH &amp; Co KG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansfeld</LastName><ForeName>Michael Dieter</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>ILV Kaernten, Veterinaermedizinische Untersuchungen, Carinthia, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duscher</LastName><ForeName>Georg G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0002-3486-5470</Identifier><AffiliationInfo><Affiliation>Austrian Agency for Health and Food Safety, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Phage (New Rochelle)</MedlineTA><NlmUniqueID>101768955</NlmUniqueID><ISSNLinking>2641-6530</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMR</Keyword><Keyword MajorTopicYN="N">Myoviridae</Keyword><Keyword MajorTopicYN="N">S. infantis</Keyword><Keyword MajorTopicYN="N">aerosol</Keyword><Keyword MajorTopicYN="N">nebulization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39372362</ArticleId><ArticleId IdType="pmc">PMC11447383</ArticleId><ArticleId IdType="doi">10.1089/phage.2023.0037</ArticleId><ArticleId IdType="pii">10.1089/phage.2023.0037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Żaczek M, Weber-Dąbrowska B, Międzybrodzki R, et al. . Phage therapy in Poland—a Centennial journey to the first ethically approved treatment facility in Europe. Front Microbiol 2020;11:1056; doi: 10.3389/fmicb.2020.01056</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01056</ArticleId><ArticleId IdType="pmc">PMC7291835</ArticleId><ArticleId IdType="pubmed">32582061</ArticleId></ArticleIdList></Reference><Reference><Citation>Briot T, Kolenda C, Ferry T, et al. PHAGEinLYON study group . Paving the way for phage therapy using novel drug delivery approaches. J Control Release 2022;347:414–424; doi: 10.1016/j.jconrel.2022.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.05.021</ArticleId><ArticleId IdType="pubmed">35569589</ArticleId></ArticleIdList></Reference><Reference><Citation>Durr HA, Leipzig ND. Advancements in bacteriophage therapies and delivery for bacterial infection. Mater Adv 2023;4(5):1249–1257; doi: 10.1039/d2ma00980c</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d2ma00980c</ArticleId><ArticleId IdType="pmc">PMC9987412</ArticleId><ArticleId IdType="pubmed">36895585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang RYK, Wallin M, Lin Y, et al. . Phage therapy for respiratory infections. Adv Drug Deliv Rev 2018;133:76–86; doi: 10.1016/j.addr.2018.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2018.08.001</ArticleId><ArticleId IdType="pmc">PMC6226339</ArticleId><ArticleId IdType="pubmed">30096336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xie Z, Zhao J, et al. . Prospects of Inhaled Phage Therapy for combatting pulmonary infections. Front Cell Infect Microbiol 2021;11:758392; doi: 10.3389/fcimb.2021.758392</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.758392</ArticleId><ArticleId IdType="pmc">PMC8685529</ArticleId><ArticleId IdType="pubmed">34938668</ArticleId></ArticleIdList></Reference><Reference><Citation>Flament MP, Leterme P, Gayot A. Study of the technological parameters of ultrasonic nebulization. Drug Dev Ind Pharm 2001;27(7):643–649; doi: 10.1081/ddc-100107320</Citation><ArticleIdList><ArticleId IdType="doi">10.1081/ddc-100107320</ArticleId><ArticleId IdType="pubmed">11694011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathammer K, Winkelmayer L, Leidwein A, et al. Disinfection with vaporized hydrogen fluid in different environments and its applications and advantages in crisis management. IDIMT-2022,2022, pp. 161–170, doi: 10.35011/IDIMT-2022-161</Citation><ArticleIdList><ArticleId IdType="doi">10.35011/IDIMT-2022-161</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutala WA, Weber DJ. Disinfection and sterilization: An overview. Am J Infect Control 2013. May;41(5 Suppl):S2–5; doi: 10.1016/j.ajic.2012.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2012.11.005</ArticleId><ArticleId IdType="pubmed">23622742</ArticleId></ArticleIdList></Reference><Reference><Citation>Strathdee SA, Hatfull GF, Mutalik VK, et al. . Phage therapy: From biological mechanisms to future direction. Cell 2023;186(1):17–31; doi: 10.1016/j.cell.2022.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.11.017</ArticleId><ArticleId IdType="pmc">PMC9827498</ArticleId><ArticleId IdType="pubmed">36608652</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022;399(10325):629–655; doi: 10.1016/S0140-6736(21)02724-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02724-0</ArticleId><ArticleId IdType="pmc">PMC8841637</ArticleId><ArticleId IdType="pubmed">35065702</ArticleId></ArticleIdList></Reference><Reference><Citation>Otter JA, Budde-Niekiel A. Hydrogen peroxide vapor: A novel method for the environmental control of lactococcal bacteriophages. J Food Prot 2009;72(2):412–414; doi: 10.4315/0362-028x-72.2.412</Citation><ArticleIdList><ArticleId IdType="doi">10.4315/0362-028x-72.2.412</ArticleId><ArticleId IdType="pubmed">19350989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JP, Richter W, Sunderman M, et al. . Evaluating the environmental persistence and inactivation of MS2 bacteriophage and the presumed Ebola virus surrogate Phi6 using low concentration hydrogen peroxide vapor. Environ Sci Technol 2020;54(6):3581–3590; doi: 10.1021/acs.est.9b06034</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.est.9b06034</ArticleId><ArticleId IdType="pmc">PMC7371032</ArticleId><ArticleId IdType="pubmed">32073830</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy PK, Ha AJ, Mizan MFR, et al. . Effects of environmental conditions (temperature, pH, and glucose) on biofilm formation of Salmonella enterica serotype Kentucky and virulence gene expression. Poult Sci 2021. Jul;100(7):101209; doi: 10.1016/j.psj.2021.101209</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psj.2021.101209</ArticleId><ArticleId IdType="pmc">PMC8182266</ArticleId><ArticleId IdType="pubmed">34089933</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung SSY, Carrigy NB, Vehring R, et al. . Jet nebulization of bacteriophages with different tail morphologies—Structural effects. Int J Pharm 2019;554:322–326; doi: 10.1016/j.ijpharm.2018.11.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.11.026</ArticleId><ArticleId IdType="pubmed">30445174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang RYK, Morales S, Okamoto Y, et al. . Topical application of bacteriophages for treatment of wound infections. Transl Res 2020;220:153–166; doi: 10.1016/j.trsl.2020.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.03.010</ArticleId><ArticleId IdType="pmc">PMC7293950</ArticleId><ArticleId IdType="pubmed">32268129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>